Fierce Pharma December 22, 2023
As the biopharma world readies for the turn of the calendar, the all-too-familiar topic of drug pricing once again presents an industry-wide overhang. In addition to the escalating regulatory scrutiny from the Biden administration in the recent months, the pharmaceutical industry can also count on political rhetoric heating up ahead of next year’s presidential election.
After a long stretch of victories for the drug industry, the Biden administration is clearly emboldened on the prospect of cracking down on pharma’s U.S. pricing freedom. Amid the government’s efforts to usher in Medicare pricing negotiations under the Inflation Reduction Act (IRA), the administration has pursued several other avenues to attempt to rein in prices or boost pharmaceutical competition. Few of them are...
Today's Sponsors
Today's Sponsor